Guochuan E Tsai

Summary

Affiliation: Los Angeles Biomedical Research Institute
Country: USA

Publications

  1. ncbi Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis
    Guochuan E Tsai
    Department of Psychiatry, Harbor UCLA Medical Center, HH2121, 1000 W Carson Street, Torrance, CA 90509, USA
    Curr Pharm Des 16:522-37. 2010
  2. ncbi D-alanine added to antipsychotics for the treatment of schizophrenia
    Guochuan E Tsai
    Department of Psychiatry, Harbor UCLA Medical Center, Torrance, California 90509, USA
    Biol Psychiatry 59:230-4. 2006
  3. ncbi Disposition of D-serine in healthy adults
    Guochuan E Tsai
    Department of Psychiatry, Harbor-UCLA Medical Center, F9, 1000 W. Carson Street, Torrance, CA 90509, USA
    J Clin Pharmacol 48:524-7. 2008
  4. ncbi Novel therapies for schizophrenia: understanding the glutamatergic synapse and potential targets for altering N-methyl-D-aspartate neurotransmission
    Christina Hui
    Department of Psychiatry, Harbor UCLA Medical Center, HH212, 1000 West Carson Street, Torrance, CA 90509, USA
    Recent Pat CNS Drug Discov 4:220-38. 2009
  5. ncbi NMDA neurotransmission as a critical mediator of borderline personality disorder
    Bernadette Grosjean
    Department of Psychiatry, Harbor UCLA Medical Center, Torrance, California 90509, USA
    J Psychiatry Neurosci 32:103-15. 2007
  6. ncbi Low cerebrospinal fluid glutamate and glycine in refractory affective disorder
    Mark A Frye
    Department of Psychiatry, University of California Los Angeles Neuropsychiatric Institute, Los Angeles, CA, USA
    Biol Psychiatry 61:162-6. 2007
  7. ncbi RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia
    Hsien Yuan Lane
    Department of Psychiatry, China Medical University and Hospital, Taichung, Taiwan
    J Clin Psychopharmacol 28:64-8. 2008
  8. ncbi Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study
    Hsien Yuan Lane
    Department of Psychiatry, China Medical University and Hospital, Taichung, Taiwan
    Biol Psychiatry 63:9-12. 2008
  9. ncbi Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study
    Hsien-Yuan Lane
    Department of Psychiatry, China Medical University and Hospital, Taichung, Taiwan
    Arch Gen Psychiatry 62:1196-204. 2005
  10. ncbi Searching for rational anti N-methyl-D-aspartate treatment for depression
    Guochuan E Tsai
    Arch Gen Psychiatry 64:1099-100; author reply 1100-1. 2007

Collaborators

Detail Information

Publications11

  1. ncbi Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis
    Guochuan E Tsai
    Department of Psychiatry, Harbor UCLA Medical Center, HH2121, 1000 W Carson Street, Torrance, CA 90509, USA
    Curr Pharm Des 16:522-37. 2010
    ..Other drug targets that may enhance NMDA neurotransmission more than the molecules tested so far need to be explored...
  2. ncbi D-alanine added to antipsychotics for the treatment of schizophrenia
    Guochuan E Tsai
    Department of Psychiatry, Harbor UCLA Medical Center, Torrance, California 90509, USA
    Biol Psychiatry 59:230-4. 2006
    ..D-alanine is another endogenous agonist of the NMDA-glycine site that might have beneficial effects on schizophrenia...
  3. ncbi Disposition of D-serine in healthy adults
    Guochuan E Tsai
    Department of Psychiatry, Harbor-UCLA Medical Center, F9, 1000 W. Carson Street, Torrance, CA 90509, USA
    J Clin Pharmacol 48:524-7. 2008
  4. ncbi Novel therapies for schizophrenia: understanding the glutamatergic synapse and potential targets for altering N-methyl-D-aspartate neurotransmission
    Christina Hui
    Department of Psychiatry, Harbor UCLA Medical Center, HH212, 1000 West Carson Street, Torrance, CA 90509, USA
    Recent Pat CNS Drug Discov 4:220-38. 2009
    ..The 21(st) century holds promise as the era in which an entirely new type of medication for schizophrenia may be created, one with more success at treating the debilitating negative and cognitive symptoms of this disease...
  5. ncbi NMDA neurotransmission as a critical mediator of borderline personality disorder
    Bernadette Grosjean
    Department of Psychiatry, Harbor UCLA Medical Center, Torrance, California 90509, USA
    J Psychiatry Neurosci 32:103-15. 2007
    ..This impairment may be the result of a combination of biological vulnerability and environmental influences mediated by the NMDA neurotransmission...
  6. ncbi Low cerebrospinal fluid glutamate and glycine in refractory affective disorder
    Mark A Frye
    Department of Psychiatry, University of California Los Angeles Neuropsychiatric Institute, Los Angeles, CA, USA
    Biol Psychiatry 61:162-6. 2007
    ..Glutamatergic dysregulation has been documented in schizophrenia but has received less systematic study in affective illness...
  7. ncbi RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia
    Hsien Yuan Lane
    Department of Psychiatry, China Medical University and Hospital, Taichung, Taiwan
    J Clin Psychopharmacol 28:64-8. 2008
    ....
  8. ncbi Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study
    Hsien Yuan Lane
    Department of Psychiatry, China Medical University and Hospital, Taichung, Taiwan
    Biol Psychiatry 63:9-12. 2008
    ..However, the efficacy of these agents as a primary antipsychotic agent has not yet been demonstrated...
  9. ncbi Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study
    Hsien-Yuan Lane
    Department of Psychiatry, China Medical University and Hospital, Taichung, Taiwan
    Arch Gen Psychiatry 62:1196-204. 2005
    ..This finding indicates that a glycine transporter 1 inhibitor may be more efficacious than NMDA-glycine site agonists for adjuvant treatment of schizophrenia, at least during the acute phase. Further studies are needed...
  10. ncbi Searching for rational anti N-methyl-D-aspartate treatment for depression
    Guochuan E Tsai
    Arch Gen Psychiatry 64:1099-100; author reply 1100-1. 2007
  11. ncbi A case series of D-cycloserine added to donepezil in the treatment of Alzheimer's disease
    William E Falk
    J Neuropsychiatry Clin Neurosci 14:466-7. 2002